procedural sedation (short-term use). Although Sanders et al present convincing evidence and demonstrate the likely mechanisms, for the harmful effects of benzodiazepines (when used for longer term sedation) in infections and sepsis, further studies will be required to better understand the exact clinical scenarios where their use is void of such effects. This is particularly important because of the widespread use of benzodiazepines for both short-term procedural sedation and longer term sedation. Finally, these studies prove that the sedative and immunosuppressive effects of benzodiazepines are mediated via different receptor subtypes and can be potentially separated once receptor subtype selective compounds are developed for clinical use.
Much remains to be learned about the exact role of benzodiazepines and GABA A receptor-mediated anesthetics on the outcome of human infections (pneumonia and sepsis). This study presents the opportunities for the development of alternative benzodiazepines that do not engage the GABAα 1 receptor subunit. These more selective agents would be void of the immunosuppressive side effects of current sedatives but would retain the sedative properties and improve the safety profile of benzodiazepines. N ot long ago, adequate sleep was generally considered a luxury rather than a health necessity. Indeed, sleeping was often linked to laziness, lack of ambition, and sloth-getting by with inadequate sleep was often considered a "badge of honor," particularly during medical training (1) .
Curtailing sleep does, unfortunately, have adverse consequences. The neurocognitive deficits associated with sleep loss have been recognized for a long time. However, it is only relatively recently that the importance of adequate sleep as one of the pillars of a healthy lifestyle (similar to exercise and a prudent diet) has been recognized. Numerous experimental studies in healthy subjects have shown adverse cardiometabolic effects of even modest durations of sleep loss, including activation of inflammation, sympathetic activation, increased cortisol, and glucose intolerance (2). These findings have complemented the epidemiologic studies that have shown a clear association between habitual short sleep and a variety of long-term health outcomes, including coronary heart disease, diabetes, obesity, hypertension, pneumonia, and death (3, 4) . Disorders of sleep fragmentation, such as obstructive sleep apnea, are also linked to poor cardiometabolic outcomes (5) .
Although a difficult area to study, the potential role of sleep in the ICU has been receiving increasing attention. Numerous studies have shown that patients in the ICU suffer from poor sleep. Objectively, sleep is more fragmented and characterized by frequent arousals and awakenings, with excessive sleep during the day and less at night (6) . Subjectively, patients report that sleep in the ICU is of poorer quality than their sleep at home (7) . Given the myriad of detrimental effects of sleep loss, it seems likely that these sleep abnormalities would have potential adverse consequences in the ICU.
Multiple factors contribute to sleep disruption in the ICU; for example, noise, light, pain, anxiety, encephalopathy, delirium, medications, and circadian rhythm abnormalities likely play roles. The role of mechanical ventilation and how we set the ventilator should also be considered. For example, both high levels of pressure support (PS) and minimal levels of PS administered to susceptible patients with high respiratory system gains (e.g., heart failure) can lead to central apneas and sleep disruption (8, 9) . High levels of PS may also lead to air trapping and ineffective triggering of the ventilator leading to patient/ventilator dyssynchrony. To make matters more complex, the choice of PS level may be state dependent, that is, dependent on whether the patient is asleep or awake (10) . For example, a particular level of PS may be appropriate during wakefulness, but upon transition to sleep, the resultant reduced carbon dioxide production, and blunting of chemosensitivity and loss of behavioral control may lower PS requirements. On the other hand, inadequate unloading of the respiratory muscles due to insufficient PS is not optimal for sleep either. Increased respiratory efforts, characterized by more negative pleural pressure, can trigger arousals from sleep (11) ; this finding suggests that assisted ventilation should have fewer respiratory-related arousals than spontaneous breathing. Ventilator modes that better match gas delivery to patient effort (such as neurally adjusted or proportional assist modes) (12, 13) may lead to less dyssynchrony and better sleep quality.
In this issue of Critical Care Medicine, Roche-Campo et al (14) extend this body of knowledge by addressing the potential impact of mechanical ventilation per se on sleep quality. The authors studied 16 conscious patients with tracheostomy who could breathe spontaneously for at least five consecutive hours. They were studied a median of 23 days after tracheostomy while weaning from mechanical ventilation. In an elegant randomized crossover study, during a single night (10 PM to 8 AM), patients were placed on 5 hours of PS ventilation (PSV) or unassisted breathing. PS was set at a level determined by the attending physician (median of 10-cm water). Sleep was assessed by polysomnography, including electroencephalogram recordings, and scored according to standard criteria. During PSV compared with unassisted breathing, patients experienced significantly more sleep (183 min vs 132 min, p = 0.04). Although not statistically significant, amounts of rapid eye movement (REM) and deep sleep were greater in the mechanical ventilation group (11 vs 3 min; 45 vs 28 min); this finding may be important given the association between lack of REM sleep and increased risk of delirium (15) . Measurement of esophageal pressure and work of breathing may have helped define the mechanistic basis of the study's findings; such measurements, although unavailable in the present study, do not take much away from the study's important findings.
Sleep fragmentation rates were similar in both arms (25 vs 23 arousals and awakenings/hr). Consistent with other studies, overall sleep efficiency (i.e., time asleep/recording time) was reduced (50%) suggesting a shift from nighttime to daytime sleep from circadian rhythm disruption or other factors.
What do these findings mean for the current practicing critical care clinician? If one believes that improving sleep is an appropriate end in and of itself (which may be reasonable given the myriad of adverse effects of sleep loss), the recommendations of the authors appear appropriate. That is, patients should be reconnected to the ventilator at night to promote sleep while being weaned from assisted to unassisted breathing. However, patients need to be followed closely at night to ensure that PS is not excessive, which could yield central apneas, patient/ventilator dyssynchrony, and sleep fragmentation. Such underlying mechanisms may have contributed to delayed weaning when PS was compared with spontaneous breathing in a recent trial (16) .
One interesting overarching question is "What will sleep mean to the future practicing critical care physician?" Fundamentally, will improving sleep lead to better patient outcomes (e.g., delirium, mortality, length of stay, and nosocomial infection)? Will we be able to monitor sleep quantity and quality without the cumbersome use of a visually scored electroencephalogram? What will be the best ways to improve sleep (environmental manipulation, pharmaceuticals, ventilator modifications, and behavioral therapies)? How should we help to ameliorate the circadian abnormalities associated with critical illness?
As physicians, we tend to focus predominately on what our patients are doing in the daytime. Perhaps, the time has come to focus more on what is happening to our patients at night? www.ccmjournal.org July 2013 • Volume 41 • Number 7 V entilator-associated pneumonia (VAP) is the most common hospital-acquired infection among patients receiving mechanical ventilation. VAP is associated with attributable costs of $25,000-$32,140 per episode, an average of 7-12.5 added days of hospitalization, and case fatality rates of 12% to 24% (1-3). As the prevalence of multidrug resistant bacteria increases, intensivists are faced with the need to prescribe initial broad-spectrum antibiotic therapy in patients with suspected VAP to avoid inappropriate treatment associated with greater mortality (1, (3) (4) (5) ; however, competing with the need to provide initial adequate therapy is the need to prevent additional antibiotic resistance. To this end, one of the simplest and most effective methods for preventing the emergence of antibiotic-resistant bacteria is the avoidance of unnecessary antibiotic use (6) .
In this issue of Critical Care Medicine, Raman et al (7) provide another study suggesting that early discontinuation of antibiotics is both safe and advantageous in the right setting. The authors conducted a retrospective, observational review evaluating the relationship between early antibiotic discontinuation after negative quantitative bronchoalveolar lavage cultures and mortality in patients with clinically suspected VAP across several ICU settings. Eighty-nine patients with clinically suspected VAP and quantitative culture results below the threshold of 10 4 colony-forming units/mL were analyzed over a 38-month period. Patients were divided into 40 patients whose antibiotics were discontinued within a day of final culture results (early discontinuation) and 49 patients whose antibiotics were stopped more than a day after final culture results (late discontinuation). The hospital did not have a protocol for antibiotic discontinuation using culture results or resolution of clinical signs of VAP. There were some notable demographic and procedural differences between the two groups, including differences in neurologic and cardiovascular diseases, use of minibronchoalveolar lavage versus bronchoscopy, and immunosuppression. However, baseline Acute Physiology and Chronic Health Evaluation II scores were similar between the two groups, and the authors attempt to account for these differences in a multivariate analysis to assess the effect of early discontinuation on mortality.
The authors were unable to demonstrate a difference in the primary outcome of mortality, as the sample size was too small to detect a significant difference. However, supporting the position that antibiotics should be discontinued when the final culture results show no significant organism, their results demonstrated that early antibiotic discontinuation was found to have significantly fewer superinfections (22.5% vs 42.9%, p = 0.008), respiratory superinfections (10.0% vs 28.6%, p = 0.036), and multidrug resistant superinfections (7.5% vs 35.7%, p = 0.003), with no significant difference in mortality (25.0% vs 30.6%, p = 0.642).
In doing so, the authors build on and compare their findings with those of Singh et al (8) and Kollef and Kollef (9) . Although each study demonstrates safety in a shorter antibiotic duration, there are some notable differences across studies. In the study by Singh et al, patients with a new-onset pulmonary infiltrate and a clinical pulmonary infection score of less than 6 were randomized to either standard therapy or ciprofloxacin monotherapy for 3 days coupled with discontinuation if the clinical pulmonary infection score remained of less than 6. Patients had been in the ICU for a mean of 9 days prior to enrollment, with only 58% receiving mechanical ventilation, suggesting that patients were more accurately being treated for late-onset hospital-associated pneumonia. In both their prospective observational study and prospective, randomized controlled trials, Kollef and colleagues used an antibiotic discontinuation guideline based on resolution of signs and symptoms of infection or identification of a noninfectious etiology of the pulmonary infiltrate, rather than culture
